Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 60 | 2024 | 2109 | 4.560 |
Why?
|
| Cognition Disorders | 29 | 2015 | 985 | 2.990 |
Why?
|
| Cognitive Dysfunction | 28 | 2023 | 1061 | 2.750 |
Why?
|
| Stroke | 17 | 2023 | 261 | 2.730 |
Why?
|
| Diet, Mediterranean | 8 | 2023 | 100 | 1.870 |
Why?
|
| Aged | 87 | 2024 | 8997 | 1.480 |
Why?
|
| Cognition | 30 | 2024 | 1339 | 1.390 |
Why?
|
| Humans | 123 | 2024 | 27072 | 1.380 |
Why?
|
| Female | 87 | 2024 | 15212 | 1.290 |
Why?
|
| Brain | 21 | 2024 | 1649 | 1.260 |
Why?
|
| Male | 84 | 2024 | 14772 | 1.230 |
Why?
|
| Dementia | 11 | 2023 | 560 | 1.160 |
Why?
|
| Aging | 15 | 2021 | 1544 | 1.140 |
Why?
|
| Aged, 80 and over | 51 | 2024 | 4777 | 1.090 |
Why?
|
| Biomarkers | 11 | 2023 | 562 | 1.080 |
Why?
|
| Chicago | 22 | 2021 | 949 | 0.990 |
Why?
|
| Stress, Psychological | 4 | 2016 | 235 | 0.920 |
Why?
|
| Neuropsychological Tests | 22 | 2021 | 1196 | 0.850 |
Why?
|
| Depression | 4 | 2022 | 444 | 0.840 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 18 | 0.810 |
Why?
|
| Diet, Western | 1 | 2022 | 11 | 0.780 |
Why?
|
| Attitude | 1 | 2022 | 34 | 0.770 |
Why?
|
| Amyloid beta-Peptides | 8 | 2024 | 324 | 0.770 |
Why?
|
| Longitudinal Studies | 30 | 2021 | 1368 | 0.770 |
Why?
|
| Cardiology | 1 | 2022 | 44 | 0.750 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 1112 | 0.740 |
Why?
|
| Risk Factors | 32 | 2023 | 2302 | 0.720 |
Why?
|
| Community Participation | 1 | 2020 | 17 | 0.700 |
Why?
|
| Disease Progression | 13 | 2023 | 673 | 0.670 |
Why?
|
| Prospective Studies | 12 | 2023 | 1778 | 0.660 |
Why?
|
| Apolipoproteins E | 12 | 2023 | 251 | 0.650 |
Why?
|
| Hypertension | 6 | 2022 | 192 | 0.640 |
Why?
|
| tau Proteins | 6 | 2023 | 232 | 0.590 |
Why?
|
| Brain Concussion | 3 | 2023 | 15 | 0.590 |
Why?
|
| Cohort Studies | 21 | 2024 | 1890 | 0.590 |
Why?
|
| Football | 3 | 2023 | 37 | 0.580 |
Why?
|
| Apolipoprotein E4 | 11 | 2021 | 263 | 0.560 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 133 | 0.550 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2013 | 28 | 0.550 |
Why?
|
| Sex Characteristics | 4 | 2023 | 116 | 0.550 |
Why?
|
| Incidence | 16 | 2023 | 759 | 0.540 |
Why?
|
| Independent Living | 5 | 2023 | 322 | 0.530 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 321 | 0.480 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 891 | 0.440 |
Why?
|
| Cerebral Infarction | 2 | 2013 | 147 | 0.440 |
Why?
|
| Middle Aged | 21 | 2023 | 8923 | 0.420 |
Why?
|
| Brain Infarction | 3 | 2023 | 75 | 0.390 |
Why?
|
| Sex Factors | 8 | 2023 | 464 | 0.390 |
Why?
|
| Dietary Approaches To Stop Hypertension | 3 | 2021 | 36 | 0.390 |
Why?
|
| Dietary Supplements | 5 | 2022 | 66 | 0.380 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 12 | 0.360 |
Why?
|
| Diet Surveys | 3 | 2022 | 25 | 0.360 |
Why?
|
| Vitamin B 12 | 2 | 2011 | 13 | 0.360 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 39 | 0.360 |
Why?
|
| Dementia, Vascular | 3 | 2007 | 46 | 0.350 |
Why?
|
| Neuroimaging | 4 | 2021 | 126 | 0.340 |
Why?
|
| Smoking | 3 | 2012 | 176 | 0.330 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 87 | 0.330 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 125 | 0.330 |
Why?
|
| Healthy Lifestyle | 4 | 2024 | 45 | 0.330 |
Why?
|
| White Matter | 3 | 2022 | 134 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 381 | 0.310 |
Why?
|
| Risk Assessment | 10 | 2022 | 624 | 0.300 |
Why?
|
| Comorbidity | 8 | 2021 | 481 | 0.300 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 131 | 0.290 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 280 | 0.290 |
Why?
|
| Memory Disorders | 4 | 2019 | 159 | 0.290 |
Why?
|
| Cerebral Arteries | 2 | 2007 | 25 | 0.290 |
Why?
|
| Women's Health | 2 | 2019 | 174 | 0.280 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 1792 | 0.280 |
Why?
|
| Time Factors | 6 | 2021 | 1433 | 0.270 |
Why?
|
| Population Surveillance | 2 | 2021 | 115 | 0.270 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 4 | 0.270 |
Why?
|
| Folic Acid | 1 | 2006 | 21 | 0.260 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 1144 | 0.260 |
Why?
|
| Parkinsonian Disorders | 3 | 2022 | 225 | 0.260 |
Why?
|
| Movement Disorders | 1 | 2006 | 66 | 0.260 |
Why?
|
| Patient Selection | 2 | 2021 | 194 | 0.260 |
Why?
|
| Urban Health | 1 | 2006 | 22 | 0.250 |
Why?
|
| Parkinson Disease | 4 | 2022 | 670 | 0.250 |
Why?
|
| Diet | 5 | 2022 | 220 | 0.240 |
Why?
|
| Vitamin D | 2 | 2022 | 39 | 0.240 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 347 | 0.240 |
Why?
|
| United States | 10 | 2022 | 2035 | 0.220 |
Why?
|
| Overweight | 2 | 2022 | 72 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2020 | 57 | 0.220 |
Why?
|
| Exercise | 4 | 2022 | 450 | 0.210 |
Why?
|
| Risk | 5 | 2015 | 204 | 0.210 |
Why?
|
| Day Care, Medical | 3 | 2008 | 6 | 0.210 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 28 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 164 | 0.200 |
Why?
|
| Life Style | 5 | 2023 | 186 | 0.200 |
Why?
|
| Gender Identity | 2 | 2023 | 26 | 0.200 |
Why?
|
| Causality | 4 | 2011 | 56 | 0.200 |
Why?
|
| Food | 1 | 2022 | 34 | 0.190 |
Why?
|
| Crime Victims | 1 | 2022 | 32 | 0.190 |
Why?
|
| Genetic Loci | 3 | 2020 | 51 | 0.190 |
Why?
|
| Genetic Testing | 1 | 2022 | 57 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2019 | 75 | 0.190 |
Why?
|
| Lutein | 1 | 2021 | 5 | 0.190 |
Why?
|
| Zeaxanthins | 1 | 2021 | 5 | 0.190 |
Why?
|
| Carotenoids | 1 | 2021 | 18 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 88 | 0.190 |
Why?
|
| Logistic Models | 6 | 2011 | 395 | 0.180 |
Why?
|
| Age Factors | 8 | 2019 | 766 | 0.180 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 12 | 0.180 |
Why?
|
| Clergy | 3 | 2006 | 92 | 0.180 |
Why?
|
| Prevalence | 5 | 2021 | 443 | 0.180 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 17 | 0.170 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 43 | 0.170 |
Why?
|
| Program Development | 1 | 2020 | 51 | 0.170 |
Why?
|
| Vertigo | 1 | 2000 | 8 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2021 | 165 | 0.170 |
Why?
|
| Endothelium | 1 | 2020 | 14 | 0.170 |
Why?
|
| Advance Care Planning | 1 | 2020 | 11 | 0.170 |
Why?
|
| Terminal Care | 1 | 2020 | 25 | 0.170 |
Why?
|
| Disability Evaluation | 2 | 2007 | 264 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 278 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2020 | 42 | 0.160 |
Why?
|
| Age Distribution | 3 | 2011 | 85 | 0.160 |
Why?
|
| Interviews as Topic | 2 | 2015 | 132 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.150 |
Why?
|
| Patient Care Management | 1 | 2018 | 16 | 0.150 |
Why?
|
| Women's Health Services | 1 | 2018 | 8 | 0.150 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 17 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 24 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 16 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 18 | 0.150 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 10 | 0.150 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 21 | 0.150 |
Why?
|
| Genotype | 3 | 2016 | 346 | 0.150 |
Why?
|
| Mortality | 2 | 2016 | 89 | 0.150 |
Why?
|
| Linear Models | 3 | 2015 | 247 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 42 | 0.140 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2017 | 1 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2018 | 53 | 0.140 |
Why?
|
| Amyloid | 3 | 2022 | 56 | 0.140 |
Why?
|
| Public Health | 1 | 2018 | 69 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 59 | 0.140 |
Why?
|
| Self Report | 2 | 2022 | 223 | 0.140 |
Why?
|
| Education | 3 | 2006 | 40 | 0.140 |
Why?
|
| Sex Distribution | 2 | 2011 | 78 | 0.140 |
Why?
|
| Cognitive Aging | 1 | 2018 | 78 | 0.130 |
Why?
|
| Homes for the Aged | 2 | 2007 | 9 | 0.130 |
Why?
|
| Nursing Homes | 2 | 2007 | 36 | 0.130 |
Why?
|
| Adult | 9 | 2023 | 7831 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 143 | 0.130 |
Why?
|
| Communication | 1 | 2017 | 104 | 0.130 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2016 | 16 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2015 | 257 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 33 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 52 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2015 | 41 | 0.120 |
Why?
|
| Residence Characteristics | 3 | 2011 | 214 | 0.120 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 101 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2012 | 79 | 0.110 |
Why?
|
| Heart Failure | 3 | 2022 | 151 | 0.110 |
Why?
|
| Bias | 2 | 2012 | 32 | 0.110 |
Why?
|
| Prognosis | 4 | 2019 | 785 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2015 | 150 | 0.110 |
Why?
|
| Antioxidants | 2 | 2005 | 63 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2011 | 270 | 0.100 |
Why?
|
| Memory | 3 | 2006 | 297 | 0.100 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 20 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 310 | 0.100 |
Why?
|
| Alleles | 4 | 2021 | 216 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 474 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2012 | 25 | 0.100 |
Why?
|
| Social Support | 1 | 2012 | 196 | 0.090 |
Why?
|
| Community Health Services | 2 | 2009 | 34 | 0.090 |
Why?
|
| Psychometrics | 2 | 2010 | 220 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 3538 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2022 | 195 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 77 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2009 | 879 | 0.090 |
Why?
|
| Neocortex | 1 | 2010 | 31 | 0.090 |
Why?
|
| Confidence Intervals | 3 | 2005 | 94 | 0.090 |
Why?
|
| Decision Support Techniques | 2 | 2010 | 47 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2023 | 114 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 127 | 0.080 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 97 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 3 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 3 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 2 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 50 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2010 | 147 | 0.080 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 135 | 0.080 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 207 | 0.070 |
Why?
|
| Community Health Nursing | 1 | 2008 | 6 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2009 | 89 | 0.070 |
Why?
|
| Home Care Services | 1 | 2008 | 22 | 0.070 |
Why?
|
| Vitamin E | 2 | 2005 | 44 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2007 | 13 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2007 | 38 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2022 | 28 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 14 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 629 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2007 | 130 | 0.060 |
Why?
|
| Postural Balance | 1 | 2007 | 117 | 0.060 |
Why?
|
| Research Design | 2 | 2021 | 185 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2007 | 141 | 0.060 |
Why?
|
| Patient Admission | 1 | 2005 | 22 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 348 | 0.060 |
Why?
|
| Hallucinations | 1 | 2005 | 42 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 8 | 0.060 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 302 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 167 | 0.050 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 11 | 0.050 |
Why?
|
| Caloric Restriction | 1 | 2023 | 16 | 0.050 |
Why?
|
| Seafood | 1 | 2003 | 13 | 0.050 |
Why?
|
| Gait | 1 | 2007 | 412 | 0.050 |
Why?
|
| Urban Population | 2 | 2003 | 153 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2003 | 39 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 8 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 329 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 85 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 6 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 7 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 27 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 29 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2022 | 51 | 0.050 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 35 | 0.050 |
Why?
|
| Frailty | 1 | 2022 | 34 | 0.050 |
Why?
|
| Atrial Appendage | 1 | 2022 | 34 | 0.050 |
Why?
|
| Vegetables | 1 | 2021 | 26 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 70 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 123 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 75 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 88 | 0.050 |
Why?
|
| Accelerometry | 1 | 2021 | 89 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 64 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2022 | 87 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 595 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 8 | 0.040 |
Why?
|
| Tremor | 1 | 2022 | 104 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2022 | 193 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 111 | 0.040 |
Why?
|
| Athletes | 1 | 2021 | 88 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2022 | 70 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 127 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 587 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 31 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 29 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2022 | 110 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 61 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 130 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 250 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Educational Status | 3 | 2007 | 293 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 344 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 14 | 0.040 |
Why?
|
| Nutrition Assessment | 3 | 2005 | 42 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 155 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 3485 | 0.040 |
Why?
|
| Survival Rate | 2 | 2011 | 342 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 261 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 3642 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 220 | 0.040 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 24 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 300 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 2 | 0.040 |
Why?
|
| Indian Ocean Islands | 1 | 2018 | 2 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 273 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 20 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 87 | 0.040 |
Why?
|
| Ambulances | 1 | 2017 | 1 | 0.040 |
Why?
|
| Pregnancy | 1 | 2018 | 336 | 0.040 |
Why?
|
| Caregivers | 1 | 2020 | 197 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2012 | 127 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 161 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 190 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 10 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 218 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2007 | 105 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 189 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2018 | 170 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 44 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2007 | 90 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2007 | 100 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 29 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 312 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 6 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 39 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 170 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 1994 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2015 | 192 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 118 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 347 | 0.030 |
Why?
|
| Markov Chains | 1 | 2012 | 33 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 599 | 0.020 |
Why?
|
| Fumarates | 1 | 2011 | 2 | 0.020 |
Why?
|
| Maleates | 1 | 2011 | 2 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 4 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2010 | 6 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 18 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 54 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2010 | 35 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 57 | 0.020 |
Why?
|
| Nursing Administration Research | 1 | 2008 | 1 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2008 | 20 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 39 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 64 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 28 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2006 | 9 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2006 | 41 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2007 | 129 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2005 | 21 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 39 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 39 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 55 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 111 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 9 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 13 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 482 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 261 | 0.010 |
Why?
|
| Models, Psychological | 1 | 2004 | 69 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 676 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 9 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 11 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 11 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Population | 1 | 2002 | 5 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 29 | 0.010 |
Why?
|
| Occupations | 1 | 2002 | 18 | 0.010 |
Why?
|
| beta Carotene | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 47 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 40 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 94 | 0.010 |
Why?
|